Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.
When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot. In a study of the three… read more.
Medtronic plc announced that the FDA has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is… read more.
Approximately one in five older adults in the U.S. is transferred to a nursing home following a hospital stay. For many of these patients, an accessible medical record does… read more.
Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.
Can AI save us from the arduous and time-consuming task of academic research collection? An international team of researchers investigated the credibility and efficiency of generative AI as… read more.
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine… read more.
Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.
At a time when more men are considering body contouring and gluteal enhancement, an Internet survey provides new information on the “ideal” appearance of the male buttock, reports the… read more.
McGill University researchers have made a breakthrough in diagnostic technology, inventing a ‘lab on a chip’ that can be 3D-printed in just 30 minutes. The chip has the… read more.
– Genentech, a member of the Roche Group announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab-kxwh)… read more.
Despite an end to the national public health emergency in May 2023, the use of telehealth remains high, with over 20% of American adults taking appointments online. These visits include… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
